
Sequential, a biotech company specialising in genomic testing from non-invasive skin samples, has closed its first equity round at $3.5 million. The round was co-led by Sparkfood and Corundum Systems Biology (CSB), with additional participation from Dermazone Holdings, SOSV, Scrum Ventures, a former General Partner at Index Ventures, and continued support from Innovate UK. Combined with prior non-dilutive grants, Sequential has now secured $7.5 million in total funding.
The personal care industry has long struggled to move beyond incremental formulation improvements. Most ingredient testing remains slow, expensive, and limited in scope. Sequential is working to change that by applying systems biology and advanced computational modelling to one of the largest proprietary clinical datasets in dermatological health.
The company's testing platform transforms complex biological data into clear, actionable product insights. By integrating both microbial and molecular analyses, Sequential enables brands, biotechs, and pharmaceutical companies to develop products and claims that are scientifically credible.
Oliver Worsley, PhD, CEO and Co-Founder, described the company's direction: "By applying artificial intelligence to one of the world's largest clinical datasets in dermatological health, we can both discover new skin biomarkers, and move beyond incremental formulation improvements and instead systematically design and validate breakthrough ingredient combinations. This investment allows us to scale that vision."
The new capital will be directed toward developing an AI-powered discovery engine built on Sequential's proprietary real-world clinical dataset. The engine is designed to predict, optimise, and identify next-generation active complexes and novel bioactive ingredients, areas where conventional testing methods are too blunt a tool for the level of precision now possible.
Sequential also plans to expand its biomarker discovery programs and deepen its global partnerships. The goal is to build a scalable platform that sets a new standard for data-driven innovation across personal care and adjacent health categories. Inflammatory conditions such as acne, atopic dermatitis, and rosacea are central to the company's scientific agenda.
Founded and led by Worsley alongside a team of PhD-level scientists, Sequential is built on a proprietary research infrastructure that is difficult to replicate. The company has amassed over 50,000 human skin microbiome samples, tested across more than 4,000 ingredients and 10,000 participants worldwide. That depth of real-world clinical data is what makes the AI discovery engine viable.
The company operates labs in Cambridge, New York City, and Singapore, and carries backing from both Innovate UK and Enterprise Singapore. It was recognised in 2022 by Cosmetics and Toiletries magazine as the most significant testing solution in the industry.
Sequential's approach sits at the intersection of the microbiome, molecular biology, and computational analysis. Rather than testing individual ingredients in isolation, the platform quantifies how formulations alter microbial and host biomarkers at a systems level, a meaningful difference from conventional testing.
Anouk Veber, Ventures' Business Unit Leader at Sparkfood, commented on the investment rationale: "Sequential has built a unique bridge between biology, clinical validation, and consumer product development, linking molecular and microbial biomarkers to real-world product performance. This investment also aligns with Sparkfood's connected innovation strategy, opening the door to co-development opportunities and commercial synergies in the personal care space."
Hidehiko Otake, CEO of Corundum Systems Biology, added: "Sequential's mission aligns with ours: to transform human health with the power of large datasets, the microbiome, and artificial intelligence. Our continued support in this round reflects our confidence in their vision and our shared commitment to redefining the future of personal care."
This round brings Sequential's total raised to $7.5 million, combining dilutive and non-dilutive sources. Prior backers include SOSV, Corundum Systems Biology, Innovate UK, Enterprise Singapore, and A*STAR's Genome Institute of Singapore, among others. Scrum Ventures and Dermazone Holdings join the cap table with this round.

